Stoke Therapeutics (STOK) EBIT (2018 - 2026)
Stoke Therapeutics' quarterly EBIT came in at -$53.4 million in Q1 2026, down 148.02% year-on-year from $111.2 million in Q1 2025, and up 13.06% quarter-over-quarter from -$61.4 million in Q4 2025.
Stoke Therapeutics has reported EBIT for 9 years, with the latest figure at -$53.4 million in Q1 2026.
- For the quarter ending Q1 2026, EBIT fell 148.02% year-over-year to -$53.4 million; the trailing twelve-month figure through Mar 2026 stood at -$185.2 million (down 584.41% YoY), and the FY2025 full-year result was -$20.6 million, up 79.69% from the prior year.
- EBIT for Q1 2026 stood at -$53.4 million, up from -$61.4 million in the prior quarter.
- The five-year high for EBIT was $111.2 million in Q1 2025, with the low at -$61.4 million in Q4 2025.
- Average EBIT over 5 years is -$23.2 million, with a median of -$27.3 million recorded in 2025.
- Peak annual rise in EBIT reached 492.08% in 2025, while the deepest fall reached 350.0% in 2025.
- Tracing STOK's EBIT over 5 years: stood at -$27.2 million in 2022, then declined by 8.87% to -$29.6 million in 2023, then surged by 53.85% to -$13.7 million in 2024, then tumbled by 350.0% to -$61.4 million in 2025, then increased by 13.06% to -$53.4 million in 2026.
- The last three EBIT figures came in at -$53.4 million (Q1 2026), -$61.4 million (Q4 2025), and -$43.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | -53.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.42 Mn |
| Dec 31, 2025 | -61.44 Mn |
| Sep 30, 2025 | -43.09 Mn |
| Jun 30, 2025 | -27.30 Mn |
| Mar 31, 2025 | 111.24 Mn |
| Dec 31, 2024 | -13.65 Mn |
| Sep 30, 2024 | -30.00 Mn |
| Jun 30, 2024 | -29.34 Mn |
| Mar 31, 2024 | -28.37 Mn |
| Dec 31, 2023 | -29.59 Mn |
| Sep 30, 2023 | -27.23 Mn |
| Jun 30, 2023 | -33.26 Mn |
| Mar 31, 2023 | -24.69 Mn |
| Dec 31, 2022 | -27.18 Mn |
| Sep 30, 2022 | -27.15 Mn |
| Jun 30, 2022 | -25.24 Mn |
| Mar 31, 2022 | -24.80 Mn |
| Dec 31, 2021 | -24.53 Mn |
| Sep 30, 2021 | -22.68 Mn |
| Jun 30, 2021 | -22.03 Mn |
| Mar 31, 2021 | -16.83 Mn |
| Dec 31, 2020 | -14.59 Mn |
| Sep 30, 2020 | -13.71 Mn |
| Jun 30, 2020 | -13.01 Mn |
| Mar 31, 2020 | -11.74 Mn |
| Dec 31, 2019 | -11.07 Mn |
| Sep 30, 2019 | -9.84 Mn |
| Jun 30, 2019 | -8.45 Mn |
| Mar 31, 2019 | -6.32 Mn |
| Dec 31, 2018 | -4.54 Mn |
| Sep 30, 2018 | -3.32 Mn |
| Jun 30, 2018 | -3.01 Mn |